Human ; Female ; Adult ; Betamethasone ; Calcitriol ; Psoriasis ; Scalp

Introduction: COVID-19 has emerged as a global problem with vaccines being established as one of the best tools in its control. Of particular interest in dermatology are risks and manifestations of cutaneous reactions from such countermeasures, with strides made in documenting and associating skin reactions with vaccines against COVID-19. This study aimed to determine the incidence of cutaneous adverse reactions in recipients of recombinant ChAdOx1-S and inactivated SARS-COV-2 vaccines among healthcare personnel and employees of UERMMMCI. Methods: A cross-sectional study was done were respondents, chosen through randomized stratified cluster sampling, were given a questionnaire to elicit cutaneous adverse effects associated with COVID-19 vaccines. Results: There were198 respondents, of which 29.3% were male and 70.7% were female, with a mean age of 26.07 years. Of these respondents, 72 (36.36%) received recombinant ChAdOx1-S and 126 (63.64%) received inactivated SARS-COV-2 vaccine. For the first dose, cutaneous reactions developed in 6 (8.33%) recipients of recombinant ChAdOx1-S, and 2 (1.59%) recipients of inactivated SARS-COV-2. For the second dose, no reactions followed vaccination with recombinant ChAdOx1-S while 4 (3.17%) reactions developed after inactivated SARS-COV-2 vaccination. Lesions were mostly confined to the injection site presenting with erythema for both vaccine types. One urticarial, widespread reaction was associated with a second dose of inactivated SARS-COV-2 vaccine. Conclusions Adverse reactions to COVID-19 vaccinations have been documented which may be attributed to respective excipients rather than vaccine antigens. Due to the rare occurrence of severe anaphylactic reactions, vaccine use is recommended as they confer protection even to those with prior infections. Documented reactions in this study were observed to be mild and self- limiting similar to larger studies.
Vaccines ; COVID-19 ; Pandemics

Introduction: Bullous pemphigoid (BP) is an acquired autoimmune subepidermal bullous disease characterized by linear depo- sition of IgG and C3 along the basement membrane. It rarely occurs in childhood, especially in adolescence, with only 14 cases identified in literature. Treatment of choice is systemic corticosteroids but other treatment options such as anti-inflammatory antibacterials and methotrexate are available. Case report: A 16-year-old Filipino girl presented with a three-month history of generalized vesicles and bullae. Nikolsky and Asboe-Hansen signs were negative. Histopathology and direct immunofluorescence were consistent with BP. ELISA to BP180 au- toantibody levels was elevated at 135 IU (normal <9 IU). Complete blood count showed leukocytosis with increase in neutrophils. Chest x-ray revealed pulmonary tuberculosis. The patient was given quadruple anti-Koch’s medication (pyrazinamide, rifampi- cin, ethambutol, isoniazid), prednisone, oral erythromycin and topical clobetasol propionate. Complete remission was attained at 10 months and is sustained at the time of writing. Conclusion To establish a definitive diagnosis and appropriate management, BP requires clinical, histopathologic, and immuno- logical correlation. Childhood BP has good prognosis and rapid treatment response, with rare relapses.
Pemphigoid, Bullous